Literature DB >> 15341735

The CAP-Gly domain of CYLD associates with the proline-rich sequence in NEMO/IKKgamma.

Kohei Saito1, Takanori Kigawa, Seizo Koshiba, Kazuo Sato, Yo Matsuo, Ayako Sakamoto, Tetsuo Takagi, Mikako Shirouzu, Takashi Yabuki, Emi Nunokawa, Eiko Seki, Takayoshi Matsuda, Masaaki Aoki, Yukako Miyata, Noriko Hirakawa, Makoto Inoue, Takaho Terada, Takahiro Nagase, Reiko Kikuno, Manabu Nakayama, Osamu Ohara, Akiko Tanaka, Shigeyuki Yokoyama.   

Abstract

CYLD was originally identified as the human familial cylindromatosis tumor suppressor. Recently, it was reported that CYLD directly interacts with NEMO/IKKgamma and TRAF2 in the NF-kappaB signaling pathway. The two proteins bind to a region of CYLD that contains a Cys-box motif and the third cytoskeleton-associated protein-glycine conserved (CAP-Gly) domain. Here we report that the third CAP-Gly domain of CYLD specifically interacts with one of the two proline-rich sequences of NEMO/IKKgamma. The tertiary structure of the CAP-Gly domain shares the five-stranded beta sheet topology with the SH3 domain, which is well known as a proline-rich sequence-recognition domain. However, chemical shift mapping revealed that the peptide binding site of the CAP-Gly domain is formed without the long peptide binding loop characteristic of the SH3 domain. Therefore, CAP-Gly is likely to be a novel proline-rich sequence binding domain with a mechanism different from that of the SH3 domain.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15341735     DOI: 10.1016/j.str.2004.07.012

Source DB:  PubMed          Journal:  Structure        ISSN: 0969-2126            Impact factor:   5.006


  38 in total

1.  Epstein-Barr latent membrane protein 1 transformation site 2 activates NF-kappaB in the absence of NF-kappaB essential modifier residues 133-224 or 373-419.

Authors:  Daniela Boehm; Benjamin E Gewurz; Elliott Kieff; Ellen Cahir-McFarland
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-05       Impact factor: 11.205

2.  A Structural View of Negative Regulation of the Toll-like Receptor-Mediated Inflammatory Pathway.

Authors:  Emine Guven-Maiorov; Ozlem Keskin; Attila Gursoy; Ruth Nussinov
Journal:  Biophys J       Date:  2015-08-11       Impact factor: 4.033

Review 3.  Specificity and versatility of SH3 and other proline-recognition domains: structural basis and implications for cellular signal transduction.

Authors:  Shawn S-C Li
Journal:  Biochem J       Date:  2005-09-15       Impact factor: 3.857

Review 4.  Reverse the curse--the role of deubiquitination in cell cycle control.

Authors:  Ling Song; Michael Rape
Journal:  Curr Opin Cell Biol       Date:  2008-03-17       Impact factor: 8.382

Review 5.  Regulation and cellular roles of ubiquitin-specific deubiquitinating enzymes.

Authors:  Francisca E Reyes-Turcu; Karen H Ventii; Keith D Wilkinson
Journal:  Annu Rev Biochem       Date:  2009       Impact factor: 23.643

Review 6.  CYLD: a tumor suppressor deubiquitinase regulating NF-kappaB activation and diverse biological processes.

Authors:  S-C Sun
Journal:  Cell Death Differ       Date:  2010-01       Impact factor: 15.828

7.  ClipR-59 interacts with Akt and regulates Akt cellular compartmentalization.

Authors:  Jixin Ding; Keyong Du
Journal:  Mol Cell Biol       Date:  2009-01-12       Impact factor: 4.272

8.  TRIM38 inhibits TNFα- and IL-1β-triggered NF-κB activation by mediating lysosome-dependent degradation of TAB2/3.

Authors:  Ming-Ming Hu; Qing Yang; Jing Zhang; Shi-Meng Liu; Yu Zhang; Heng Lin; Zhe-Fu Huang; Yan-Yi Wang; Xiao-Dong Zhang; Bo Zhong; Hong-Bing Shu
Journal:  Proc Natl Acad Sci U S A       Date:  2014-01-13       Impact factor: 11.205

9.  HSV ICP0 recruits USP7 to modulate TLR-mediated innate response.

Authors:  Sandrine Daubeuf; Divyendu Singh; Yaohong Tan; Hongiu Liu; Howard J Federoff; William J Bowers; Khaled Tolba
Journal:  Blood       Date:  2008-10-24       Impact factor: 22.113

Review 10.  Molecular basis of NF-κB signaling.

Authors:  Johanna Napetschnig; Hao Wu
Journal:  Annu Rev Biophys       Date:  2013-03-11       Impact factor: 12.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.